CIA

J&J marketing triggers $2.2B payout

J&J marketing triggers $2.2B payout

By

The company will shell out $2.2 billion over allegations of marketing misconduct for Risperdal, Invega and Natrecor.

Novartis sued for alleged speaker-program abuse

By

The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

By

Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.

CIAs pressure pharma to rethink sales rep compensation

By

Novartis's recent off-label settlement with the Department of Justice -- to the tune of $422 million -- also included the signing of a Corporate Integrity Agreement (CIA) requiring the Swiss-based manufacturer to review incentive-based compensation for reps, and to examine "the extent to which compensation is based on product performance," according to the CIA.

Sales reps at J&J unit to get 'ride-alongs' as part of CIA

By

As part of an $81 million off-label settlement with the Department of Justice (DOJ), Ortho-McNeil Janssen Pharmaceuticals Inc. (OMJPI) sales reps will be buddied up with internal compliance monitors tasked with observing and reporting the rep's behavior out in the field.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.